Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma

Expert Review of Anticancer Therapy

Volumn 6, Issue 6, 2006, Pages 905-909

  Curti, Brendan D ^a  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

Author keywords

Cytokine; Interleukin 15; Interleukin 18; Interleukin 2; Interleukin 21; Natural killer cells; Renal cell carcinoma; T cells

Indexed keywords

ALPHA INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE RECEPTOR; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; INTERLEUKIN 7; SORAFENIB; SUNITINIB; INTERLEUKIN DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CHILL; CLINICAL TRIAL; CONSTIPATION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG PROTEIN BINDING; DRUG RESPONSE; EDEMA; FATIGUE; FEVER; GENE SEQUENCE; HEADACHE; HEMOPTYSIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; KIDNEY CARCINOMA; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MELANOMA; MYALGIA; NATURAL KILLER CELL; NAUSEA; NONHUMAN; REVIEW; SEQUENCE HOMOLOGY; T LYMPHOCYTE; ANIMAL; DISEASE MODEL; IMMUNOLOGY; KIDNEY TUMOR; MOUSE;

ANIMALS; B-LYMPHOCYTES; CARCINOMA, RENAL CELL; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKINS; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; MICE; T-LYMPHOCYTES;

EID: 33745139171     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.6.905     Document Type: Review

References (22)

1. Parrish-Novak J, Dillon SR, Nelson A et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408, 57-63 (2000).
2. Leonard WJ, Spolski R. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat. Rev. Immunol. 5, 688-698 (2005).
3. Strengell M, Sareneva T, Foster D et al. IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. J. Immunol. 169, 3600-3605 (2002).
4. + T cell expansion and function. J. Exp. Med. 201, 139-148 (2005).
5. Strengell M, Matikainen S, Siren J et al. IL-21 in synergy with IL-15 or IL-18 enhances IFN-γ production in human NK and T cells. J. Immunol. 170, 5464-5469 (2003).
6. Gays F, Martin K, Kenefeck R et al. Multiple cytokines regulate the NK gene complex-encoded receptor repertoire of mature NK cells and T cells. J. Immunol. 175, 2938-2947 (2005).
7. Ozaki K, Spolski R, Feng CG et al. A critical role for IL-21 in regulating immunoglobulin production. Science 298, 1630-1634 (2002).
8. Cohen L, de Moor C, Parker PA et al. Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccine. Urol. Oncol. 7, 119-124 (2002).
9. Curti BD. Renal cell carcinoma. JAMA 292, 97-100 (2004).
10. Quesada JR, Swanson DA, Trindade A et al. Renal cell carcinoma: antitumor effects of leukocyte interferon. Cancer Res. 43, 940-947 (1983).
11. Fossa SD. Interferon in metastatic renal cell carcinoma. Semin. Oncol. 27, 187-193 (2000).
12. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21, 3127-3132 (2003).
13. Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin. Cancer Res. 10, S6342-S6346 (2004).
14. McDermott DF, Regan MM, Clark JI et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23, 133-141 (2005).
15. Hughes S, Chin L, Waggle K et al. Interleukin-21 efficacy in a mouse model of metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 22(Suppl. 187) (2004).
16. Curti BD, Redman BG, Thompson JA et al. Preliminary tolerability and anti-tumor activity of intravenous recombinant human Interleukin-21 (IL-21) in patients with metastatic melanoma and metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 23(Suppl. 166) (2005).
17. Thompson JA, Redman BG, Curti BD et al. Identification of a well-tolerated outpatient regimen of intravenous recombinant human interleukin-21 (IL-21) in patients with metastatic melanoma and metastatic renal cell carcinoma. Int. Soc. Biol. Ther. Cancer 20, 32 (2005).
18. Aronson FR, Libby P, Brandon EP et al. IL-2 rapidly induces natural killer cell adhesion to human endothelial cells. A potential mechanism for endothelial injury. J. Immunol. 141, 158-163 (1988).
19. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16-24 (2006).
20. Walker EB, He H, Yang G et al. In vivo synergy of IL-21 plus IL-2 in a murine transgenic PMEL-1 therapeutic melanoma tumor model results in significant anti-tumor immunity and durable long-term curative effect. Int. Soc. Biol. Ther. Cancer 20, 59 (2005).
21. Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9, 802-811 (2003).
22. Escudier B, Szczylik C, Eisen T et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. 23(Suppl. 380) (2005).